Market Overview

TearLab Corporation Reports First Quarter 2019 Financial Results

Share:

ESCONDIDO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) ("TearLab" or the "Company") today reported its consolidated financial results for the first quarter ended March 31, 2019. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

Recent Highlights

  • First quarter revenue of $5.7 million
  • Cash position of $8.9 million as of March 31, 2019, an increase from $8.5 million as of December 31, 2018
  • May, 2019 annual meeting of American Society of Cataract and Refractive Surgery (ASCRS) introduced the ASCRS ‘Algorithm for Preoperative Diagnosis and Treatment of Ocular Surface Disease' – which includes osmolarity testing as part of the ‘essential screening battery' of pre-operative diagnostic tests

For the three months ended March 31, 2019, TearLab's net revenues were $5.7 million, down 10.9% from $6.4 million for the same period in 2018.

The following table sets out the estimated annualized revenue per U.S. device and account analysis for the first quarter ended March 31, 2019

            Annualized   Annualized
    Active   Active   Revenue   Revenue
Program   Devices   Accounts   Per Device   Per Account
Purchased   1,169   981   $   2,162   $   2,576
Masters   1,740   210   $   2,758   $   22,849
Flex   1,888   634   $   6,881   $   20,492
Total   4,797   1,825        

The Company's reported net loss for the 2019 first quarter was approximately $1.3 million, or ($0.12) basic loss per share, compared to a reported net loss of approximately $0.9 million, or ($0.09) basic loss per share in the first quarter of 2018. 

"We were pleased to report another quarter of positive cash flows and operating income, which demonstrates the stability of our current business. We are also excited about the impact of this week's release by ASCRS for their Algorithm for Preoperative Diagnosis and Treatment Ocular Surface Disease.  We believe the increased interest and activity in the dry eye space creates continued growth opportunities for our current generation TearLab Osmolarity System.  In addition, we continue to work diligently to complete the resubmission of our 510(k) application for FDA clearance of the next generation Discovery™ platform" said Seph Jensen, TearLab's Chief Executive Officer.

About TearLab Corporation 
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the OTCQB Market under the symbol 'TEAR'.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, the ability to capitalize on the current market momentum for osmolarity and to bring the Tearlab Discovery™ system to the U.S. market. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements.  Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2018. We do not undertake to update any forward-looking statements except as required by law.

CONTACT: Investor Contact: 
The Ruth Group 
Janhavi Mohite 
Tel: 646-536-7026 
jmohite@theruthgroup.com



 
TearLab Corp.
Condensed Consolidated Statements of Operations
(Expressed in U.S. Dollars (000's) except for number of shares and net loss per share)
(Unaudited)


    Three months
     ended December 31,
      2019       2018  
Revenue        
  Product sales   $   4,996     $   5,775  
  Reader equipment rentals     687         671  
Total revenue     5,683       6,446  
Cost of goods sold        
Cost of goods sold  (excluding amortization of intangible assets)     1,930       1,836  
Cost of goods sold - reader equipment depreciation     153       288  
Gross profit     3,600       4,322  
Operating expenses        
Sales and marketing     875       1,020  
Clinical, regulatory and research & development      874         1,041  
General and administrative     1,844         2,044  
Total operating expenses     3,593         4,105  
Income from operations     7         217  
Other income (expense)     (1,346 )        (1,100 )
Net loss and comprehensive loss   $   (1,339 )   $   (883 )
Weighted average shares outstanding     11,559,220          9,526,122  
Net loss per share   $   (0.12 )   $   (0.09 )
         


TearLab Corp.
Condensed Consolidated Balance Sheets
(Expressed in U.S. Dollars (000's)


  March 31,   December 31,
  2019     2018  
           
ASSETS          
Current assets          
Cash   $   8,860       $   8,473  
Accounts receivable, net       1,098           1,186  
Inventory       2,207           1,987  
Prepaid expenses and other current assets       632           690  
Total current assets     12,797         12,336  
           
Fixed assets, net     1,797         2,024  
Right of Use assets     738        
Intangible assets, net     2         2  
Other non-current assets     150         151  
Total assets   $   15,484       $   14,513  
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current liabilities          
Accounts payable   $   1,319       $   681  
Accrued liabilities     1,920         2,363  
Deferred revenue/rent     7         13  
Current portion of lease liability     221         -  
Current portion of long-term debt     7,981         -  
Total current liabilities     11,448         3,057  
           
Long-term debt, net of current portion       25,381           32,014  
Long-term 3rd party payable       113           111  
Long-term lease liability, net of current portion       518          
           
Total liabilities     37,460         35,182  
Commitments and contingencies (Note8)          
           
Stockholders' deficit          
Capital stock          
Preferred Stock, $0.001 par value, 10,000,000 authorized, 380 and 556 and  issued and
outstanding at March 31, 2019 and December 31, 2018, respectively
      -            -   
Common stock, $0.001 par value, 40,000,000 authorized, 11,696,998 and 11,296,998 issued and
outstanding at March 31, 2019 and December 31, 2018, respectively
    12         11  
Additional paid-in capital     510,411         510,380  
Accumulated deficit       (532,399 )         (531,060 )
Total stockholders' deficit       (21,976 )         (20,669 )
Total liabilities and stockholders' deficit   $   15,484       $   14,513  

 

View Comments and Join the Discussion!